Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Phase 3 Pivotal Study to Evaluate the Safety and Efficacy of TOOKAD (Padeliporfin) Vascular Targeted Photodynamic Therapy in the Treatment of Low Grade Upper Tract Urothelial Cancer

NCT04620239 is registered in ClinicalTrials.gov with Steba Biotech S.A. as lead sponsor.

NCT NCT04620239
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04620239 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Phase 3 Pivotal Study to Evaluate the Safety and Efficacy of TOOKAD (Padeliporfin) Vascular Targeted Photodynamic Therapy in the Treatment of Low Grade Upper Tract Urothelial Cancer
Lead sponsor
Steba Biotech S.A.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
March 22, 2021
Completion date
August 1, 2028
Enrollment
89 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

transitional cell cancer of renal pelvis and ureter